Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia

Peter Breslin

doi:10.1007/978-981-13-7342-8

Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia

Peter Breslin

Department of Biology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Despite the significant progress that has been made in understanding the biology of leukemia stem cells (LSCs), some key questions regarding the concept of LSCs have not as yet been satisfactorily addressed experimentally. As a result, the clinical relevance of LSCs remains less than clear due to controversies caused largely by technical limitations in efficiently identifying LSCs. This has impeded our ability to fully address the features of genetic heterogeneity and metabolic/epigenetic plasticity of pre-LSCs and LSCs. With the development and use of humanized immunocompromised mice, we are able to more precisely analyze LSCs for their functions and interaction with the bone marrow niche. In addition, some promising targets in LSCs have recently been identified, including Sonic Hedgehog (SHH) and BCL-2, which are highly expressed in AML cells. It is hopeful that new anti-LSC compounds will be tested fully in clinical trials for their efficacy in treating human leukemias.

Original language	American English
Title of host publication	Leukemia Stem Cells in Hematologic Malignancies
DOIs	https://doi.org/10.1007/978-981-13-7342-8
State	Published - 2019

Keywords

leukemia stem cell
humanized immunocompromised mice
AML

Disciplines

Medicine and Health Sciences

Access to Document

10.1007/978-981-13-7342-8License: Unspecified

Cite this

@inbook{c8168cf2436e459d8f0c19a93ccf6194,

title = "Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia",

abstract = " Despite the significant progress that has been made in understanding the biology of leukemia stem cells (LSCs), some key questions regarding the concept of LSCs have not as yet been satisfactorily addressed experimentally. As a result, the clinical relevance of LSCs remains less than clear due to controversies caused largely by technical limitations in efficiently identifying LSCs. This has impeded our ability to fully address the features of genetic heterogeneity and metabolic/epigenetic plasticity of pre-LSCs and LSCs. With the development and use of humanized immunocompromised mice, we are able to more precisely analyze LSCs for their functions and interaction with the bone marrow niche. In addition, some promising targets in LSCs have recently been identified, including Sonic Hedgehog (SHH) and BCL-2, which are highly expressed in AML cells. It is hopeful that new anti-LSC compounds will be tested fully in clinical trials for their efficacy in treating human leukemias.",

keywords = "leukemia stem cell, humanized immunocompromised mice, AML",

author = "Peter Breslin",

year = "2019",

doi = "10.1007/978-981-13-7342-8",

language = "American English",

booktitle = "Leukemia Stem Cells in Hematologic Malignancies",

}

TY - CHAP

T1 - Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia

AU - Breslin, Peter

PY - 2019

Y1 - 2019

N2 - Despite the significant progress that has been made in understanding the biology of leukemia stem cells (LSCs), some key questions regarding the concept of LSCs have not as yet been satisfactorily addressed experimentally. As a result, the clinical relevance of LSCs remains less than clear due to controversies caused largely by technical limitations in efficiently identifying LSCs. This has impeded our ability to fully address the features of genetic heterogeneity and metabolic/epigenetic plasticity of pre-LSCs and LSCs. With the development and use of humanized immunocompromised mice, we are able to more precisely analyze LSCs for their functions and interaction with the bone marrow niche. In addition, some promising targets in LSCs have recently been identified, including Sonic Hedgehog (SHH) and BCL-2, which are highly expressed in AML cells. It is hopeful that new anti-LSC compounds will be tested fully in clinical trials for their efficacy in treating human leukemias.

AB - Despite the significant progress that has been made in understanding the biology of leukemia stem cells (LSCs), some key questions regarding the concept of LSCs have not as yet been satisfactorily addressed experimentally. As a result, the clinical relevance of LSCs remains less than clear due to controversies caused largely by technical limitations in efficiently identifying LSCs. This has impeded our ability to fully address the features of genetic heterogeneity and metabolic/epigenetic plasticity of pre-LSCs and LSCs. With the development and use of humanized immunocompromised mice, we are able to more precisely analyze LSCs for their functions and interaction with the bone marrow niche. In addition, some promising targets in LSCs have recently been identified, including Sonic Hedgehog (SHH) and BCL-2, which are highly expressed in AML cells. It is hopeful that new anti-LSC compounds will be tested fully in clinical trials for their efficacy in treating human leukemias.

KW - leukemia stem cell

KW - humanized immunocompromised mice

KW - AML

U2 - 10.1007/978-981-13-7342-8

DO - 10.1007/978-981-13-7342-8

M3 - Chapter

BT - Leukemia Stem Cells in Hematologic Malignancies

ER -